International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 107 | Views: 202

Research Paper | Medicine Science | India | Volume 4 Issue 4, April 2015


A Prospective Comparison of the Ondansetron Plus Aprepitant, Versus Ondansetron for the Prevention of Chemotherapy Induced Nausea and Vomiting

T. Siva Rama Krishna | G. Lakshmi Durga | Pamidi. Pradeep | P. Chandra Sai


Abstract: OBJECTIVE The objective of study is to compare Ondansetron plus Aprepitant versus Ondansetron-s safety for the prevention of chemotherapy induced nausea and vomiting in patients receiving Cisplatin and 5-Fluorouracil as their treatment for managing cervix cancer and head and neck cancer. METHODS The study was conducted in a Radiotherapy Department of tertiary care teaching hospital. Patients with cervix cancer and head and neck cancer who were scheduled to receive treatment with cisplatin and 5-fluorouracil were randomized to receive 1 of 2 treatment regimens, the standard therapy group received intravenous ondansetron 8 mg and intravenous dexamethasone 4 mg on Days 1-3. The aprepitant group received oral aprepitant 125 mg, intravenous ondansetron 8 mg, and oral dexamethasone 4 mg on Day 1, oral aprepitant 80 mg and oral dexamethasone 8 mg once daily on Days 2-3. RESULTS Of the 86 patients screened 82 were randomized. Twenty-seven (75 %) of 36 patients achieved a CR in the acute phase (days 1 through 5) on the aprepitant cycle, and fourteen (32.5 %) of 43patients had a CR on the placebo cycle. In the delayed phase (days 6 through 8), 23 (64 %) of the patients on the aprepitant cycle had a CR, and 21 (48.8 %) of the patients on the placebo cycle achieved CR. The overall number of patients with CR for days 1through 8 was 19 (52.7 %) on the aprepitant cycle compared with 12 (27.9 %) on the placebo cycle. CONCLUSION There was a significant improvement in complete response rate with aprepitant combined with a 5HT3-RA and dexamethasone as on par with 5HT3-RA and dexamethasone alone.


Keywords: Aprepitant, Ondansetron, chemotherapy, nausea and vomiting


Edition: Volume 4 Issue 4, April 2015,


Pages: 2193 - 2195


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top